Skin Sensitization Potential of a New Nicotine Patch

Smoking Cessation Clinical Trial

Official title:

Study on the Skin Sensitization Potential of a New Nicotine Transdermal Therapeutic System (TTS). A Double Blind, Randomized, Repeat Patch Test, Single Center Phase I Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00967070
• Other study ID #: A6431084
• Status: Completed
• Phase: Phase 1
• First received: August 25, 2009
• Last updated: July 6, 2012
• Start date: May 2005
• Est. completion date: August 2005

Study information

• Verified date: July 2012
• Source: Johnson & Johnson Consumer and Personal Products Worldwide
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Ethics Commission
• Study type: Interventional

Clinical Trial Summary

An investigation on the skin sensitization potential of a new nicotine patch. Evaluation of the potential of a new nicotine transdermal patch to cause sensitization in the skin after repeated applications.

Description:

Study on the skin sensitization potential of a new nicotine transdermal therapeutic system (TTS). A double blind, randomized, repeat patch test, single center phase I study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 257
• Est. completion date: August 2005
• Est. primary completion date: August 2005
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Healthy male and female subjects between 18 and 65 years

• Heavy smokers (more than 10 cigarettes per day)

• Having had no febrile or infectious illness for at least seven days prior to the first administration of the investigational product.

• Women practicing one or a combination of the following methods of birth control:

hormonal contraceptives, condoms, sponge, foams, jelly, diaphragm, or intrauterine device or women who are surgically sterilized.

• Subjects having normal skin without excessive hair growth on tested areas.

• Evidence of a personally signed and dated informed consent document indicating that the subjects has been informed of all pertinent aspects of the trial.

• Subjects who are willing to comply with scheduled visits, treatment plan and other trial procedures.

Exclusion Criteria:

• Any visible skin disorder or abnormal skin pigmentation which, in the opinion of the investigator, would interfere with the outcome of the trial

• Dermatologic disease that might interfere with the evaluation of the test site reaction

• History of chronic, dermatological, medical, or physical conditions which would, in the opinion of the investigator, preclude topical application of the test products and/or influence the outcome of the test (in particular, any immunosuppressive condition)

• Clinically relevant abnormal findings on the physical examination

• A baseline score in skin reaction assessments other than "0" on the areas to be patched

• Pregnant (verified by beta-hCG-test in urine) and/or nursing women

• Demonstrating any active physical disease, acute or chronic

• Any suspicion, history or evidence of alcohol or drug abuse

• Any history of drug hypersensitivity, asthma, urticaria or other severe allergic diathesis as well as current hay fever

• Any current or past history of chronic or recurrent metabolic, renal, hepatic, pulmonary, gastrointestinal, neurological, endocrinological, immunological, psychiatric or cardiovascular disease, myopathies, epileptic seizures and bleeding tendency.

• Recent myocardial infarct (within the last 3 months), unstable or deteriorating angina pectoris, coronary artery vasospasm (Prinzmetal's angina), serious cardiac arrythmias and acute stroke [added according to Amendment No. 1].

• Use of any medication within 4 weeks prior to the first treatment or during the trial which, in the opinion of the investigator, may influence the trial results or the safety of the subjects.

• Use of systemic or topical analgesics or antihistamines within 72 hours prior to trial enrollment (except paracetamol) or systemic or topical corticosteroids within 3 weeks of trial enrollment.

• Subjects having used nicotine products other than cigarettes within the 3 months preceding the trial

• Subjects who cannot avoid, throughout the duration of the trial, any swimming, any washing of the back and sauna or any intense physical activity that might result in excessive sweating

• Known sensitivity to adhesive tape

• Known sensitivity to any component of the test products

• History of irritation to topically applied products

• Fissure or injury of the skin at the test area

• Participation in the treatment phase of a clinical trial within 30 days prior to the treatment phase of this trial or within 10 times the respective elimination half-life of the investigational drug

Study Design

Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Screening

Related Conditions & MeSH terms

• Smoking Cessation

Intervention

Drug:
• Nicotine Patch
25 mg nicotine patch applied on the assigned marked sites on the lower back. Induction phase (21 days): left side, six treatment applications for 48 or 72 h. Challenge phase (five days): right side, one treatment application for 48 h.
• Placebo Patch
Placebo patch applied on the assigned marked sites on the lower back. Induction phase (21 days): left side, six treatment applications for 48 or 72 h. Challenge phase (five days): right side, one treatment application for 48 h.

Locations

Country	Name	City	State
Germany	IKP GmbH	Mannheim

Sponsors (1)

Lead Sponsor	Collaborator
McNeil AB

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cumulative Individual Irritation Scores		15 or 30 min, and 24, 48, and 72 hr post-application, depending on trial phase	No
Secondary	Individual Irritation Score (IIS)		15 or 30 min, and 24, 48, and 72 hr post-application, depending on trial phase	No
Secondary	Patch adhesion score		directly before patch removal	No
Secondary	Tolerability		at each visit	No